VIRGINIA RETIREMENT SYSTEMS ET Al lowered its position in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 54.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 7,238 shares of the company’s stock after selling 8,700 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Twist Bioscience were worth $1,399,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of TWST. Choreo LLC grew its holdings in shares of Twist Bioscience by 6.9% in the third quarter. Choreo LLC now owns 7,452 shares of the company’s stock valued at $1,440,000 after acquiring an additional 483 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Twist Bioscience by 22.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,102 shares of the company’s stock worth $2,253,000 after purchasing an additional 2,191 shares during the period. Radnor Capital Management LLC bought a new stake in Twist Bioscience in the third quarter worth about $271,000. Signaturefd LLC raised its holdings in shares of Twist Bioscience by 94.3% in the 3rd quarter. Signaturefd LLC now owns 548 shares of the company’s stock worth $106,000 after purchasing an additional 266 shares during the period. Finally, Sterling Capital Management LLC lifted its position in shares of Twist Bioscience by 903.2% during the 3rd quarter. Sterling Capital Management LLC now owns 2,187 shares of the company’s stock valued at $423,000 after buying an additional 1,969 shares during the last quarter.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. BWS Financial restated a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a research report on Friday, September 18th. UBS Group initiated coverage on Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective for the company. Leerink Partners upped their price objective on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Robert W. Baird raised their target price on shares of Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, Jefferies Financial Group began coverage on shares of Twist Bioscience in a research report on Thursday, October 8th. They set a “hold” rating and a $150.00 target price for the company. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $153.00.
Get Our Latest Analysis on TWST
Insider Buying and Selling at Twist Bioscience
In other Twist Bioscience news, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the sale, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. The trade was a 8.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 4,548 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $202.15, for a total value of $919,378.20. Following the transaction, the chief executive officer owned 562,760 shares in the company, valued at $113,761,934. This trade represents a 0.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 601,920 shares of company stock worth $93,768,202. Insiders own 3.08% of the company’s stock.
Twist Bioscience Stock Up 1.6%
TWST opened at $142.58 on Thursday. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average price is $152.59 and its 200-day moving average price is $90.28. The company has a market cap of $8.94 billion, a P/E ratio of -64.22 and a beta of 2.25. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $219.71.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the company posted $0.33 earnings per share. On average, equities analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Twist Bioscience Profile
Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.
Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.
Featured Stories
- Five stocks we like better than Twist Bioscience
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
